normal granulocytes, appear to contain mainly TC III.
A B S T R A C T Unsaturated vitamin B12-binding capacity (UBBC) of human serum is not reproducibly measurable because it increases variably in vitro in relation to time, temperature, and, in the case of plasma, anticoagulant present before removal of cells. This variable increase proved to be due to variable release in vitro of transcobalamin III (TC III) from granulocytes. UBBC increase was greatest (up to fourfold normal levels) in the presence of lithium, which is the heparin salt used in many laboratories doing UBBC studies. In vitro increase was least when blood was collected in EDTA at 00C and immediately centrifuged at 00C (To sample); results equivalent to To were obtained at room temperature even after several hours delay when 47 mM fluoride was present; either cold temperature or 47 mM fluoride appeared to prevent TC III release from granulocytes. The measured levels of the three transcobalamins with To methods of collection, which presumably reflect most closely the in vivo circulating levels, suggest that TC I and TC III in normal plasma are of the same order of magnitude and together normally comprise less than 10% of the UBBC.
Approximately 90% of the UBBC content of sonicates of peripheral blood granulocytes and of bone marrow aspirates of normal individuals appears to be TC III, with the rest being TC I. Thus, normal myelocytes, like
INTRODUCTION
It has become increasingly apparent that normal circulating human plasma may contain three rather than two major vitamin Bra binders (1) (2) (3) (4) (5) (6) . Some studies (1, 4) had concluded that the binding of Br2 to a plasma component other than the two established binders, transcobalamin I (TC I)1 and transcobalamin II (TC II) was due to secondary binding of Br2 to weak nonspecific binders and only at high concentrations of the vitamin. This view, together with the concept of the complementary roles of TC I as "storage" binder and TC II as "trans-port" binder (7, 8) , tended to exclude a third binder as of no importance. However, a third binder, designated TC III, proved capable not only of binding B22 at low concentrations of the vitamin (9) but also of binding Ba2 administered orally in man (10) . Precluding consideration of this binder because of lack of an apparent "functional" role now also seems less valid since it appears that TC I may also lack a functional role (11) , even though it carries endogenous B,2 in the circulation.
The current study addresses itself to the following considerations pertaining to TC III: its derivation from granulocytes, factors relating to its release from granulocytes, and its relationship to TC I in normal subjects. Even though TC I and TC III have no currently known function, their interrelationship within the granulocyte and their levels in the circulation may prove of value in differential diagnosis of true from pseudomyelopoliferative disorders.
The present study reaffirms variation in the unsaturated B12 binding capacity (UBBC) noted previously by ourselves and others when different anticoagulants are used to collect samples (12) (13) (14) (15) (16) and suggests these differences are related to different degrees of release of TC III by granulocytes in vitro, which may be eliminated by collection of blood in sodium fluoride.
METHODS
Collection of blood samples. Blood samples were collected directly into the appropriate Vacutainer tube (Becton-Dickinson & Co., Rutherford, N. J.). The following tube types were used: "red tops" (3200) containing no anticoagulant for collection of serum; plasma samples were collected in Vacutainer tubes with a 10-ml draw, including "lavender tops" (3200XF40) containing 15 mg of EDTA (K3) /tube; "green tops" (3208KA) containing sodium heparin, 134 USP U/tube; "grey tops" (3200XF42) containing 20 mg of sodium fluoride and 10 mg EDTA (Na2)/tube; green tops (3200LH) containing lithium heparin 143 USP U/tube; "black tops" (3200NAX) containing 0.5 ml of 0.1 M sodium oxalate. When sodium citrate was used it was added to red-top Vacutainer tubes so as to yield a final (i.e., after blood was added) concentration of 0.4%o of sodium citrate. When lithium was used other than in the lithium heparin Vacutainers mentioned above, it was added as 50 MI/5 ml blood as a saline solution of lithium chloride of the appropriate concentration.
Subjects. Blood samples were taken from normal individuals between the ages of 25 and 45. All normal subjects had normal serum and red blood cell folate levels (17) and normal B22 levels (12) and had no known gastrointestinal or hematological disorders. None were receiving medication at the time of or within 2 wk before blood donation. In all instances, the nature of the study was made known to the subjects before the donation of blood, and informed consent was obtained. Most subjects were colleagues. In each instance a complete blood count and peripheral blood smear was routinely obtained.
Vitamin B18. (12, 18) .
Control experiments using plasma of known UBBC showed that NaF, EDTA, or lithium at concentrations up to 10 times those used in this study had no effect upon the UBBC assay per se. Similarly, various other metabolic inhibitors used in an attempt to suppress UBB*C release had no artifactual effect on the assay at the concentrations used.
Chromatography. Ion exchange chromatography was carried out on DEAE cellulose as described (2) and modified (5) previously. Since the UBBC varied over a wide range, the procedure adopted was to determine the UBBC first, as described above. Just before chromatography an amount of B22 that exceeded the binding capacity by 20% was added. After incubation at 370C for 30 min, 1 ml of hemoglobin-coated charcoal was added, and the volume was adjusted to 3.0 ml with water. After centrifugation the supernate was decanted and applied to the column. Gel filtration studies of plasma samples and the pooled fractions eluted during DEAE cellulose chromatography were carried out on Sephadex G-200 as previously reported. (5) .
Sonication studies. Marrow samples containing 5 X 106 cells/ml were sonicated in 5.0-ml portions in red-top Vacutainer 10-ml test tubes. Granulocytes were sonicated in a similar manner, but the preparation differed as follows: peripheral blood sonicates were prepared by centrifuging 5.0 ml of whole blood collected in EDTA at 0C. The plasma was removed, the volume was readjusted to 10.0 ml with saline, and the content of the tube was gently mixed. The supernates were removed by centrifugation, and the volume was readjusted to 5 ml with saline. Alternatively, 0.02 M sodium phosphate buffer was used instead of saline. Both procedures gave essentially the same results. A white cell count was determined before sonication in each instance. The washing procedure removed contamination from the plasma transcobalamins, and in the case of the buffer, washing removed in addition the majority of the red cell ). The microtip probe was used for these studies with the power control set at 2.0, which gave a reference meter reading of 100. After sonication a repeat of the cell count confirmed that sonication disrupted in excess of 95% of the white cells.
Removal of TC II with uncoated charcoal. TC II was adsorbed out of plasma by a slight modification of a previously described method (3). 300 mg uncoated charcoal (Norit A) ' was added per 2 ml of plasma. The suspensions, after being agitated for a few seconds, were incubated at 370C for 30 min in a Dubnoff shaking waterbath. Every 5 min the tubes were removed and mixed by inversion. After incubation the charcoal was removed by centrifugation at 3,400g at 4°C. If charcoal remained in the supernate it was precipitated by recentrifugation under identical conditions. Preparation of platelets. Blood from a normal donor was collected in a plastic syringe without anticoagulant. Immediately, 9.0 ml was transferred to a siliconized tube that contained 1.0 ml of 4% trisodium citrate dihydrate. The tube was mixed gently by inversion and centrifuged at room temperature for 10 min at 160g. The top of the supernate (which was cloudy) was removed. The supernate was recentrifuged at 40g for 10 min, and the plateletrich supernate, relatively free of white cells, was removed.
Cell counts were made of the platelet-rich supernate and the white cell-rich precipitate. The preparation showed 6,740 red cells/ml, 14 white cells/ml, and 14,300 platelets/ ml.
Preparation of white cells. To cataway, N. J.) was added (20) . This was allowed to stand for 1 h in ice. Most of the supernate was removed and centrifuged at 250g for 10 min. Three washings with saline/citrate (5 parts saline, 1 part 4% trisodium citrate dihydrate) were carried out by suspending the cells in 20 ml, centrifuging at 250g for 10 min, removing the supernates and repeating the process two more times. All of the above was carried out at 40C. The original supernate and the three washes were kept on ice after preparation. UBBC estimation were carried out on the washings to ensure that no binder was lost during this process. Cell counts for red cells, white cells, and platelets were carried out on all preparations. Blood smears were also obtained from each preparation. The preparation showed (per ml) 9,580 red cells, 2,900 white cells, and 5,000 platelets. Preparation of blood cells without granulocytes. In a plastic syringe 27 ml of blood was obtained from a severely neutropenic subjects. To this was added 3.0 ml of 4%o trisodium citrate dihydrate in a siliconized tube. After being gently mixed the tube was allowed to stand at 4VC for 1 h. A preparation of cells was taken from the bottom of the tube and contained (per ml) 3,700,000 red cells, 740 white cells, and 286,000 platelets.
Each of the above cell preparations were divided in three: one third was sonicated for 3 min at 0C; the second third was used to obtain a To sample by centrifuging off the cells at 4VC immediately after preparation; the last third was used to obtain a To plus lithium sample by incubating at room temperature for 24 h in a final concentration of 50 meq/liter lithium chloride before removal of the cells. (Table II) . These increases were due almost exclusively to an increase in TC III (Table II) .
RESULTS

Effect
The increase when lithium was present appeared to be due to the lithium ion itself, as manifested by the fact that it could be effected by lithium in the presence of various anticoagulants or when no anticoagulant was present, i.e. lithium added to blood (Table I) . Sodium fluoride appeared to stop the action of lithium on UBBC release effectively, even over a 24-h period, although in 24 h some release did occur (Tables I and II) . Neither lithium nor sodium fluoride nor EDTA had any effect on the UBBC assay when added to control plasma or sera, even at concentrations ten times those ordinarily used in these experiments.
Comparison of UBBC values of serum as compared to plasma obtained by collection in NaF/EDTA. Since serum is the usual sample for UBBC estimation, a comparison of UBBC values of serum versus plasma collected at the same time in NaF/EDTA was made (Table  III) . Serum values always proved higher than those of NaF/EDTA plasma, and the serum values were unpredictable in extent above the NaF/EDTA plasma UBBC baseline (Table III) .
Establishment of a new normal range for UBBC. Since previous methods of collection took no precautions to stop the release of TC III after the collection of the sample, since it was not recognized such release was substantial, all prior reported UBBC values, whether in normals or in various clinical disorders, are probably higher than circulating values. The current study therefore strove to establish a new normal mean and range, using 12 normal adult men and 10 normal adult women. The results are presented in Table III and are considerably lower than in prior reports, being 640±168 pg/ ml for the men and 809±232 pg/ml for the women. This new "true" or "base-line" normal range presumably is a close approximation of the circulating UBBC rather than being above it, as is probably the case for all prior reports.
Determination of the concentration of lithium for maximum UBBC release from granulocytes. Lithium concentrations up to approximately 90 meq/liter of blood increased the quantity of UBBC released over a 24-h period (Fig. 1 ). Higher lithium concentrations were inhibitory. The exact relationship between maximal release of UBBC and lithium concentration varied In subsequent studies on lithium-stimulated release of UBBC, 50 meq lithium/liter was chosen as a suitable working concentration, since although it was below the peak area, it always effected substantial release of UBBC. In these and subsequent studies where lithium was added, EDTA was always present as an anticoagulant (15 mg/10 ml of blood). It should be noted that the high (47 mM) concentration of fluoride variably reduced the ability to measure endogenous B12 by radioassay, although it had no such effect on measuring UBBC. Therefore, endogenous B12 levels should be measured in specimens not exposed to high fluoride concentrations.
Time course of UBBC release in the presence and absence of lithium. UBBC release both in the presence and absence of lithium follows a sigmoidal shape curve. The action of lithium was to accelerate the process greatly (Fig. 2) .
Studies on the nature of the binder released by whole blood. The type of binder released by granulocytes from whole blood, both in the presence and absence of lithium stimulation, was determined by ion exchange chromatography (Fig. 3) and gel filtration on Sephadex G-200 (Fig. 4) . This was done by determining the elution profile in the starting plasma samples (To) and in the samples that had been allowed to release their UBBC for 24 h (T24). The release both in the absence (Fig. 3a) and presence (Fig. 3b) (Table V) , these cells also contain a much higher content of TC III than TC I (Table V) .
Effect of metabolic inhibitors is delineated in at a concentration of 1 mM. None of the above inhibitors had any effect on the UBBC assay when added just before assay.
Origin primarily in granulocytes of the TC III secreted in vitro. Following the protocol outlined in the Methods section, preparations of white cells, platelets, and peripheral blood cells almost devoid of granulocytes were obtained. UBBC estimations were carried out on the lithium-stimulated TC III increments of these preparations (Table VII) . Only in the case of the white cell preparation was there any increase in UBBC upon incubation for 24 h with lithium. The To values in each instance represent the UBBC present at the start of the incubation, i.e., the original plasma. Demonstration that the in vitro increment is almost exclusively TC III. When TC II is removed by uncoated charcoal and TC I and III are then separated by DEAE-cellulose, the TC II values are subject to a 10-15% error, and it may appears that some TC II increment has occurred (Table II) . This error is avoided by using both DEAE cellulose and Sephadex G-200 chromatography; by such methodology there is no increment in TC II, only a very slight increment in TC I, and the in vitro increment is almost exclusively TC III (Fig. 5) . (Tables I and III ). This appears in serum to be partly dependent upon how effectively granulocytes are held within the clot and the time taken for the clot to form. This is an important consideration, since "serum UBBC" is currently the standard UBBC in many laboratories.
The current study aimed in part to develop a method for obtaining a uniform normal UBBC, because of wide variance reported from laboratory to laboratory. In our initial investigations we found that collection of the blood sample in EDTA into a tube at 0C with rapid equilibration of the blood to that temperature and rapid centrifugation at 40C gave the lowest UBBC. We subsequently found that sodium fluoride (with EDTA as anticoagulant) was an effective inhibitor of the release of TC III from granulocytes and provided even lower and more consistent results than collection in the cold, possibly because blood comes out of the vein at 370C and takes time to cool even when immediately placed on ice (Table   TABLE IV (Table VI) . Sodium arsenate at 1 mM was also partly effective in preventing UBBC release. With EDTA-NaF for blood collection, 12 normal adult men showed a UBBC range of 380-921 pg/ml (mean: 640), and 10 normal adult women had a UBBC range of 505-1,208 pg/ml (mean: 809). A higher normal range was found for serum (611-2,036), similar to the ranges of the order of approximately 600-2,200 pg/ml reported previously (4, (22) (23) (24) (25) (26) presumably due to the release of TC III from the cells in vitro after collection in prior studies. The current studies suggest that for uniformity, reproducibility, and similarity to the levels in vivo, samples should be collected in EDTA-47 mM NaF when UBBC levels are desired. That the granulocytes were the source of the UBBC released in vitro was shown by the studies with different formed elements. It was clear (29) .
but such release The current studies emphasize the relationship beere present in sub-tween release of B12-binder from blood cells in vitro (15, 16, 27) , nature of anticoagulant used in blood colby fluoride, apart lection (12) (13) (14) (15) (16) , and UBBC level. Like Gullberg (16) , :o obtain a UBBC we found that there is less of a UBBC increment in -ulating UBBC, is vitro in EDTA plasma than in serum or heparinized ously reported that plasma (Table I ), but the current study goes on to
ler is localized in demonstrate that the in vitro increment in UBBC in found that the re-EDTA plasma is unacceptably high as compared to NaF/ es is inhibited by EDTA plasma or even citrate plasma (Table I) . aerobic glycolysis.
The finding in the current study that TC III dominol, sodium azide, nates in sonicates of normal granulocytes supports a id 2-deoxyglucose, similar earlier finding that "P-globulin" B12 binder domi-,ns. A similar pat-nates in such sonicates, as measured by DEAE-cellulose release of TC III chromatography (6) . In such chromatography, 8-globrestingly, in vitro ulin B1 binder is TC II plus TC III, and there is no been reported to TC II in granulocytes. The previous studies in which UBBC release by granulocytes was investigated (27) used gel filtration to identify the product released. That product was the single filtrate peak that would contain both TC I and TC III, since these two TCs are not separated by gel fractionation.' In the present study, extracts of granulocytes were prepared by sonication and fractioned not only by gel filtration but also by ion exchange chromatography, which does separate TC I and TC III.
The existence of two granulocyte-derived binders may be of importance. For example, in a recent study (30) * that purified the granulocyte binder, it was unclear whether this was TC I, TC III, or a mixture of the two. The finding that most of the granulocyte binder is TC III suggests that the binder purified by Allen and 20 25 30 Majerus (30) (27, 31, 32) While the granulocyte may not be the sole source of TC 1 and TC III, the fact that both occur in the granulocyte explains the correlation (33) of Bnz-binding "a-globulin" (which is TC I) with blood granulocyte pool. It also explains the similar correlation to a lesser degree (33) with Bu-binding ",f-globulin,,' because "beta" contains both TC III and TC II, and TC II is not found in granulocytes, but rather appears to be liver-derived (7) .
The high UBBC previously reported (34) in patients taking lithium therapy may be partly due to in vivo release of UBBC from granulocytes by lithium.
Because of the wide variability of UBBC results in prior studies, it was not possible in the past to establish normal saturation of circulating TBBC, other than to estimate that normally TBBC was approximately onethird to one-fifth saturated (7) . The current study, by establishing a new normal range of UBBC, makes it possible to establish more firmly the normal saturation and range of TBBC. The current study also demonstrates that UBBC is higher in adult women than in men, presumably under a similar control to that which produces UBBC rise in pregnancy (7) . The possibility of an association between TC III and glycophorin arose because that major glycoprotein of the human erythrocyte menibrane is extracted by a lithium salt (35) , and lithium stimulates TC 1II release from granulocytes. Drs. I. Kahane and V. T. Marchesi supplied us with 5 mg of freeze-dried human red blood cell (type A+) glycophorin; it proved to have negligible (5 pg/ml) B12-binding capacity.
Note added after acceptance of manuscript. In this study, we noted that grey-top Vacutainer tubes (no. 3200-XF42) containing 20 mg of sodium fluoride and 10 mg EDTA (Na2) per tube, while ideal for collecting blood samples to get true base-line levels of UBBC, could not be used for measurement of serum vitamin Ba level, because, for unknown reasons, the fluoride caused B,2 level to appear low as measured by radioassay. In unpublished studies, we have studied this problem, and now the same sample of plasma collected in fluoride may be of use for both measurement of vitamin Br2-binding capacity and of plasma vitamin B,2 level. The cause of the problem proved to be that fluoride minimizes the partial destruction of intrinsic factor concentrate that occurs in the presence of the acid used in radioassay for vitamin B,2, and thus samples containing fluoride should be measured against an intrinsic factor concentrate standard that also contains fluoride, rather than against an intrinsic factor concentrate without added fluoride. Alternatively, instead of adding fluoride to the intrinsic factor concentrate, the acid can be neutralized after the heating step and before adding the intrinsic factor concentrate.
Ascorbate ingestion may also produce artifactually low serum B12 levels (39) by minimizing the partial destruction of intrinsic factor concentrate which occurs in the presence of acid. Also building on the current studies, new studies have demonstrated that TC I is released by normal granulocyte precursors (40) , and that Quso G32 (a microfine precipitated silica of Philadelphia Quartz Co., Philadelphia, Pa.) has a much more selective affinity than uncoated charcoal for TC II (41) . In earlier work with E. Jacob, we had observed that peripheral blood cells from patients with myeloproliferative disorders released into their incubation medium a considerably greater amount of TC I in relation to TC III than did peripheral blood cells from normal persons.
